Selank: Research Overview

Selank is a synthetic hexapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Structurally, it is an analogue of the endogenous immunomodulatory tetrapeptide tuftsin, with additional amino acids appended to improve metabolic stability. Since its development, Selank has attracted research attention for its apparent anxiolytic and nootropic properties in preclinical models, as well as its potential effects on the immune system and central nervous system signaling.

Mechanism of Action

Research suggests that Selank influences the GABAergic system — the primary inhibitory neurotransmitter system in the brain — without binding directly to GABA receptors in the same manner as benzodiazepines. It appears to modulate the expression of brain-derived neurotrophic factor (BDNF) and may affect serotonin metabolism and enkephalin breakdown. Studies in rodent models have also documented interactions with the interleukin-6 pathway, suggesting a possible immunomodulatory role. The compound’s resistance to enzymatic degradation gives it a longer effective research window compared to tuftsin itself.

Key Research Areas

• Anxiolytic Effects in Animal Models: Multiple studies in rodents have observed reduced anxiety-like behavior in elevated plus maze and open field tests following Selank administration, without the sedation typically seen with GABAergic drugs.
• Cognitive Function Research: Preclinical models have examined Selank’s influence on memory consolidation and learning tasks, with some studies reporting improvements in associative learning paradigms.
• Immune System Modulation: Research has explored the peptide’s effects on T-cell activity and cytokine expression, particularly in models of immune dysregulation.
• Neurotrophin Expression: Studies suggest Selank may upregulate BDNF expression in the hippocampus, a region critical for memory formation and neuroplasticity.

Research Applications

Selank is used in neurological and immunological research settings, primarily in rodent models. It is commonly administered intranasally or via injection in preclinical studies, and its relative stability makes it suitable for repeated-dosing protocols. Researchers studying stress-related behavior, cognitive performance under load conditions, and immune-neurological interactions have found it a useful research tool. It is also sometimes included in comparative studies alongside other anxiolytic compounds.

Storage and Handling

Selank is provided as a lyophilized powder and should be stored at -20°C, protected from moisture and light. For research use, reconstitution is typically performed with sterile bacteriostatic water. Once reconstituted, the solution should be stored at 2–8°C and used within 28 days. Multiple freeze-thaw cycles should be avoided, as they can compromise peptide integrity. Standard aseptic technique is recommended for all handling.

Available from Alpha Peptides US

Researchers can source Selank 10mg from Alpha Peptides US. Each vial is intended for qualified laboratory and research applications.

This product is intended for laboratory research purposes only. It is not approved by the FDA and is not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition.